<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD01950000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P36507</UniProt_ID>
  <Seq_Length>400</Seq_Length>
  <Molecule_Weight>44424</Molecule_Weight>
  <KEGG_ID>hsa:5605</KEGG_ID>
  <Orthology_ID>K04369</Orthology_ID>
  <EBI_ID>EBI-1056930</EBI_ID>
  <Function_Summary>Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).</Function_Summary>
  <Catalytic_Mechanism>ATP + a protein = ADP + a phosphoprotein.</Catalytic_Mechanism>
  <Pfam_ID>PF00069:Pkinase</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>13</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>MAPKK 2</Alias>
      <Alias>MAPK/ERK kinase 2</Alias>
      <Alias>MAP kinase kinase 2</Alias>
      <Alias>MEK 2</Alias>
      <Alias>ERK activator kinase 2</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.</Detail>
      <Keyword>Kinase activity</Keyword>
      <Ontology_ID>GO:0016301</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.</Detail>
      <Keyword>ATP binding</Keyword>
      <Ontology_ID>GO:0005524</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.</Detail>
      <Keyword>Nucleotide binding</Keyword>
      <Ontology_ID>GO:0000166</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate.</Detail>
      <Keyword>Protein serine/threonine kinase activity</Keyword>
      <Ontology_ID>GO:0004674</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + a protein tyrosine = ADP + protein tyrosine phosphate.</Detail>
      <Keyword>Protein tyrosine kinase activity</Keyword>
      <Ontology_ID>GO:0004713</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>57</Position>
      <Original>Phe</Original>
      <Variation>Cys</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of binding to toll-like receptor 3.</Detail>
      <Keyword>Toll-like receptor 3 signaling pathway</Keyword>
      <Ontology_ID>GO:0034138</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of an epidermal growth factor receptor binding to one of its physiological ligands.</Detail>
      <Keyword>Epidermal growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0007173</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A cascade of protein kinase activities, culminating in the phosphorylation and activation of either the ERK1 or ERK2 kinases, which in turn are a subfamily of mitogen-activated protein (MAP) kinases.</Detail>
      <Keyword>ERK1 and ERK2 cascade</Keyword>
      <Ontology_ID>GO:0070371</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of molecular signals within the cell that are mediated by a member of the Ras superfamily of proteins switching to a GTP-bound active state.</Detail>
      <Keyword>Ras protein signal transduction</Keyword>
      <Ontology_ID>GO:0007265</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of binding to toll-like receptor 2.</Detail>
      <Keyword>Toll-like receptor 2 signaling pathway</Keyword>
      <Ontology_ID>GO:0034134</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of molecular signals in which a stress-activated MAP kinase cascade relays one or more of the signals; MAP kinase cascades involve at least three protein kinase activities and culminate in the phosphorylation and activation of a MAP kinase.</Detail>
      <Keyword>Stress-activated MAPK cascade</Keyword>
      <Ontology_ID>GO:0051403</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of the nerve growth factor receptor binding to one of its physiological ligands.</Detail>
      <Keyword>Nerve growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0048011</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of signal transduction mediated by the stress-activated MAPK cascade.</Detail>
      <Keyword>Regulation of stress-activated MAPK cascade</Keyword>
      <Ontology_ID>GO:0032872</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of the insulin receptor binding to insulin.</Detail>
      <Keyword>Insulin receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0008286</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals initiated by binding of an extracellular ligand to the Toll receptor on the surface of the target cell.</Detail>
      <Keyword>Toll signaling pathway</Keyword>
      <Ontology_ID>GO:0008063</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemotaxis process that directs the migration of an axon growth cone to a specific target site in response to a combination of attractive and repulsive cues.</Detail>
      <Keyword>Axon guidance</Keyword>
      <Ontology_ID>GO:0007411</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens.</Detail>
      <Keyword>Innate immune response</Keyword>
      <Ontology_ID>GO:0045087</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of binding to toll-like receptor 4.</Detail>
      <Keyword>Toll-like receptor 4 signaling pathway</Keyword>
      <Ontology_ID>GO:0034142</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands.</Detail>
      <Keyword>Fibroblast growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0008543</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The initiation of the activity of the inactive enzyme MAP kinase kinase by phosphorylation by a MAPKKK.</Detail>
      <Keyword>Activation of MAPKK activity</Keyword>
      <Ontology_ID>GO:0000186</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of binding to a toll-like receptor where the TRIF adaptor mediates transduction of the signal. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate innate immune response.</Detail>
      <Keyword>TRIF-dependent toll-like receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0035666</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the rate, frequency or extent of Golgi inheritance. Golgi inheritance is the partitioning of Golgi apparatus between daughter cells at cell division.</Detail>
      <Keyword>Regulation of Golgi inheritance</Keyword>
      <Ontology_ID>GO:0090170</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of binding to a toll-like receptor where the MyD88 adaptor molecule mediates transduction of the signal. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate innate immune response.</Detail>
      <Keyword>MyD88-dependent toll-like receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0002755</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of binding to toll-like receptor 1.</Detail>
      <Keyword>Toll-like receptor 1 signaling pathway</Keyword>
      <Ontology_ID>GO:0034130</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>396</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>226</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>222</Position>
      <PTM_Type>O-acetylserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>293</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>295</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>394</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>226</Position>
      <PTM_Type>O-acetylserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>1</Position>
      <PTM_Type>N-acetylmethionine</PTM_Type>
    </PTM>
    <PTM>
      <Position>222</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>23</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRGLAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADLKMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV</Protein_Seq>
    <DNA_Seq>CCCCTGCCTCTCGGACTCGGGCTGCGGCGTCAGCCTTCTTCGGGCCTCGGCAGCGGTAGCGGCTCGCTCGCCTCAGCCCCAGCGCCCCTCGGCTACCCTCGGCCCAGGCCCGCAGCGCCGCCCGCCCTCGGCCGCCCCGACGCCGGCCTGGGCCGCGGCCGCAGCCCCGGGCTCGCGTAGGCGCCGACCGCTCCCGGCCCGCCCCCTATGGGCCCCGGCTAGAGGCGCCGCCGCCGCCGGCCCGCGGAGCCCCGATGCTGGCCCGGAGGAAGCCGGTGCTGCCGGCGCTCACCATCAACCCTACCATCGCCGAGGGCCCATCCCCTACCAGCGAGGGCGCCTCCGAGGCAAACCTGGTGGACCTGCAGAAGAAGCTGGAGGAGCTGGAACTTGACGAGCAGCAGAAGAAGCGGCTGGAAGCCTTTCTCACCCAGAAAGCCAAGGTCGGCGAACTCAAAGACGATGACTTCGAAAGGATCTCAGAGCTGGGCGCGGGCAACGGCGGGGTGGTCACCAAAGTCCAGCACAGACCCTCGGGCCTCATCATGGCCAGGAAGCTGATCCACCTTGAGATCAAGCCGGCCATCCGGAACCAGATCATCCGCGAGCTGCAGGTCCTGCACGAATGCAACTCGCCGTACATCGTGGGCTTCTACGGGGCCTTCTACAGTGACGGGGAGATCAGCATTTGCATGGAACACATGGACGGCGGCTCCCTGGACCAGGTGCTGAAAGAGGCCAAGAGGATTCCCGAGGAGATCCTGGGGAAAGTCAGCATCGCGGTTCTCCGGGGCTTGGCGTACCTCCGAGAGAAGCACCAGATCATGCACCGAGATGTGAAGCCCTCCAACATCCTCGTGAACTCTAGAGGGGAGATCAAGCTGTGTGACTTCGGGGTGAGCGGCCAGCTCATCGACTCCATGGCCAACTCCTTCGTGGGCACGCGCTCCTACATGGCTCCGGAGCGGTTGCAGGGCACACATTACTCGGTGCAGTCGGACATCTGGAGCATGGGCCTGTCCCTGGTGGAGCTGGCCGTCGGAAGGTACCCCATCCCCCCGCCCGACGCCAAAGAGCTGGAGGCCATCTTTGGCCGGCCCGTGGTCGACGGGGAAGAAGGAGAGCCTCACAGCATCTCGCCTCGGCCGAGGCCCCCCGGGCGCCCCGTCAGCGGTCACGGGATGGATAGCCGGCCTGCCATGGCCATCTTTGAACTCCTGGACTATATTGTGAACGAGCCACCTCCTAAGCTGCCCAACGGTGTGTTCACCCCCGACTTCCAGGAGTTTGTCAATAAATGCCTCATCAAGAACCCAGCGGAGCGGGCGGACCTGAAGATGCTCACAAACCACACCTTCATCAAGCGGTCCGAGGTGGAAGAAGTGGATTTTGCCGGCTGGTTGTGTAAAACCCTGCGGCTGAACCAGCCCGGCACACCCACGCGCACCGCCGTGTGACAGTGGCCGGGCTCCCTGCGTCCCGCTGGTGACCTGCCCACCGTCCCTGTCCATGCCCCGCCCTTCCAGCTGAGGACAGGCTGGCGCCTCCACCCACCCTCCTGCCTCACCCCTGCGGAGAGCACCGTGGCGGGGCGACAGCGCATGCAGGAACGGGGGTCTCCTCTCCTGCCCGTCCTGGCCGGGGTGCCTCTGGGGACGGGCGACGCTGCTGTGTGTGGTCTCAGAGGCTCTGCTTCCTTAGGTTACAAAACAAAACAGGGAGAGAAAAAGCAAAAAAAAAAAAAAAAAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytosol</CellLocal>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>MAP2K2</Gene_Name>
    <Gene_Alias>MEK2; MKK2; PRKMK2</Gene_Alias>
    <Gene_ID>5605</Gene_ID>
    <Genbank_ACCN>NM_030662</Genbank_ACCN>
    <Protein_ACCN>NP_109587</Protein_ACCN>
    <HGNC_ID>6842</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/5605</Gene_URL>
    <UCSC_ID>uc002lzj.3</UCSC_ID>
    <EMBL_ID>ENSG00000126934</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P10398</Uniprot_ID>
      <Gene_Name>ARAF</Gene_Name>
      <EBI_ID>EBI-365961</EBI_ID>
      <PPI_EBI_URL>EBI-1056930,EBI-365961</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Leopard Syndrome</Disease_Name>
      <Disease_Detail>Leopard Syndrome</Disease_Detail>
      <Disease_DB>LPR002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leopard_syndrome?search=MAP2K2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Costello Syndrome</Disease_Name>
      <Disease_Detail>Costello Syndrome</Disease_Detail>
      <Disease_DB>CST001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/costello_syndrome?search=MAP2K2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cardiofaciocutaneous Syndrome 3</Disease_Name>
      <Disease_Detail>Cardiofaciocutaneous Syndrome</Disease_Detail>
      <Disease_DB>CRD164</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cardiofaciocutaneous_syndrome_3?search=MAP2K2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cardiofaciocutaneous Syndrome 2</Disease_Name>
      <Disease_Detail>Cardiofaciocutaneous Syndrome</Disease_Detail>
      <Disease_DB>CRD163</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cardiofaciocutaneous_syndrome_2?search=MAP2K2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Neurofibromatosis-Noonan Syndrome</Disease_Name>
      <Disease_Detail>Neurofibromatosis</Disease_Detail>
      <Disease_DB>NRF008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/neurofibromatosis_noonan_syndrome?search=MAP2K2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cardiofaciocutaneous Syndrome 4</Disease_Name>
      <Disease_Detail>Cardiofaciocutaneous Syndrome</Disease_Detail>
      <Disease_DB>CRD167</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cardiofaciocutaneous_syndrome_4?search=MAP2K2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Map2k2-Related Cardiofaciocutaneous Syndrome</Disease_Name>
      <Disease_Detail>Cardiofaciocutaneous Syndrome</Disease_Detail>
      <Disease_DB>MP2003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/map2k2_related_cardiofaciocutaneous_syndrome?search=MAP2K2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cardiofaciocutaneous Syndrome</Disease_Name>
      <Disease_Detail>Cardiofaciocutaneous Syndrome</Disease_Detail>
      <Disease_DB>CRD013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cardiofaciocutaneous_syndrome?search=MAP2K2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Noonan Syndrome</Disease_Name>
      <Disease_Detail>Noonan Syndrome</Disease_Detail>
      <Disease_DB>NNN003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/noonan_syndrome?search=MAP2K2#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>X-ray structure of the human mitogen-activated protein kinase kinase 2 (MEK2)in a complex with ligand and MgATP</PDB_Title>
      <PDB_ID>1S9I</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?pdbId=1S9I</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD01950002</ASD_Ligand>
      <Ligand_Name>5-{3,4-DIFLUORO-2-[(2-FLUORO-4-IODOPHENYL)AMINO]PHENYL}- N-(2-MORPHOLIN-4-YLETHYL)-1,3,4-OXADIAZOL- 2-AMINE$ADENOSINE-5'-TRIPHOSPHATE</Ligand_Name>
      <PubMed_Title>Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition</PubMed_Title>
      <Author>Ohren JF, et al.</Author>
      <Journal>Nat Struct Mol Biol. 2004 Dec;11(12):1192-7</Journal>
      <PubMed_ID>15543157</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04010</Pathway_ID>
      <Pathway_Title>MAPK signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a+b)</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.e.daa.b.b.gj.html</SCOP_URL>
    <CATH_Class>Mixed alpha-beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1s9i</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Detail>site,145,Ile;site,103,Ile;site,130,Ile;site,220,Ile;site,131,Val;site,223,Met;site,234,Met;site,147,Met;site,216,Ser;site,122,Leu;site,119,Leu;site,219,Leu;site,213,Phe;site,101,Lys</Site_Detail>
      <Site_Reference>Ohren JF, et al. Nat.Struct.Mol.Biol. 2004,11(12):1192-1197.</Site_Reference>
      <PDB_ID>1S9I</PDB_ID>
      <PubMed_ID>15543157</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>2.7.12.2</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/12/2.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD01940005</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01940063</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01940064</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01940095</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01940096</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01940097</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01940098</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01940099</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01941033</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01950001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01950002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01950003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01950004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>